key: cord-0873466-b0jjt298
authors: Li, Dapeng; Edwards, Robert J.; Manne, Kartik; Martinez, David R.; Schäfer, Alexandra; Alam, S. Munir; Wiehe, Kevin; Lu, Xiaozhi; Parks, Robert; Sutherland, Laura L.; Oguin, Thomas H.; McDanal, Charlene; Perez, Lautaro G.; Mansouri, Katayoun; Gobeil, Sophie M.C.; Janowska, Katarzyna; Stalls, Victoria; Kopp, Megan; Cai, Fangping; Lee, Esther; Foulger, Andrew; Hernandez, Giovanna E.; Sanzone, Aja; Tilahun, Kedamawit; Jiang, Chuancang; Tse, Longping V.; Bock, Kevin W.; Minai, Mahnaz; Nagata, Bianca M.; Cronin, Kenneth; Gee-Lai, Victoria; Deyton, Margaret; Barr, Maggie; Von Holle, Tarra; Macintyre, Andrew N.; Stover, Erica; Feldman, Jared; Hauser, Blake M.; Caradonna, Timothy M.; Scobey, Trevor D.; Rountree, Wes; Wang, Yunfei; Moody, M. Anthony; Cain, Derek W.; DeMarco, C. Todd; Denny, Thomas N.; Woods, Christopher W.; Petzold, Elizabeth W.; Schmidt, Aaron G.; Teng, I-Ting; Zhou, Tongqing; Kwong, Peter D.; Mascola, John R.; Graham, Barney S.; Moore, Ian N.; Seder, Robert; Andersen, Hanne; Lewis, Mark G.; Montefiori, David C.; Sempowski, Gregory D.; Baric, Ralph S.; Acharya, Priyamvada; Haynes, Barton F.; Saunders, Kevin O.
title: In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies
date: 2021-06-18
journal: Cell
DOI: 10.1016/j.cell.2021.06.021
sha: 727fa42674ff811b2285a301b555e1daa3bd7501
doc_id: 873466
cord_uid: b0jjt298

SARS-CoV-2 neutralizing antibodies (NAbs) protect against COVID-19. A concern regarding SARS-CoV-2 antibodies is whether they mediate disease enhancement. Here, we isolated NAbs against the receptor-binding domain (RBD) and the N-terminal domain (NTD) of SARS-CoV-2 spike from individuals with acute or convalescent SARS-CoV-2 or a history of SARS-CoV infection. Cryo-electron microscopy of RBD and NTD antibodies demonstrated function-specific modes of binding. Select RBD NAbs also demonstrated Fc receptor-γ (FcγR)-mediated enhancement of virus infection in vitro, while five non-neutralizing NTD antibodies mediated FcγR-independent in vitro infection enhancement. However, both types of infection-enhancing antibodies protected from SARS-CoV-2 replication in monkeys and mice. Three of 46 monkeys infused with enhancing antibodies had higher lung inflammation scores compared to controls. One monkey had alveolar edema and elevated bronchoalveolar lavage inflammatory cytokines. Thus, while in vitro antibody-enhanced infection does not necessarily herald enhanced infection in vivo, increased lung inflammation can rarely occur in SARS-CoV-2 antibody-infused macaques.

128 (Figure 2C ). The epitopes of Abs DH1041, DH1042, and DH1043 overlapped with that of the ACE-2 receptor 129 (Wec et al., 2020) , consistent with their ability to block ACE-2 binding to S protein (Figures 2A and S3A Ab DH1044 was only slightly shifted relative to DH1041, DH1042 and DH1043 (Figure 2C ), but resulted in 133 DH1044 not blocking ACE2 binding (Figures 2A and S3A-B) . The remaining two RBD Abs, DH1045 and 134 DH1047, cross-reacted with both SARS-CoV and SARS-CoV-2 S (Figures 2A and S2A-B) . DH1047 

NTD Abs also segregated into two clusters where one cluster included neutralizing NTD Abs and a second 159 cluster included non-neutralizing NTD Abs (Figures 3A and 3C) . NSEM reconstructions confirmed that the Fabs 160 of neutralizing NTD Ab DH1050.1 and infection-enhancing NTD Ab DH1052 could simultaneously bind to 161 distinct epitopes on a single SARS-CoV-2 S trimer ( Figure 3D ). DH1054 was unique as it was able to block both (Figures 3A-F) was obtained when we examined neutralization by DH1043 (Figures 3H and S4A-C) . In 21 SARS-CoV-2-infected 177 humans, RBD and NTD serum IgG titers were comparable (Figures S4D-E) . Moreover, the prevalence of DH1052 178 versus DH1041 Abs was assessed using blocking assays and found to be only modestly higher for DH1052 ( Figure   179 S4F 2020b) with at least one RBD in the "up" position (Figure 4 and Data S1). We did not find any unliganded S or 188 any 3-RBD-down S population, although unliganded S-2P consistently shows a 1: (Figure 4C and Data S1). DH1047 also contacted RBD residues 500-506 outside the RBM, and stacked 197 against the N-terminal end of the α3 helix. The DH1047 paratope included heavy chain HCDR2, HCDR3 and light 198 chain LCDR1 and LCDR3. The HCDR3 stacks against and interacts with the residues in the ß2 strand. Interactions 199 with the ß2 strand are also mediated by HCDR2. Similar to DH1041 and DH1043, the DH1047 interacted with an 200 "up" RBD conformation from an adjacent protomer although these interactions were not well-characterized due to 201 disorder in that region.

We next determined cryo-EM structures of the NTD-directed neutralizing Abs, DH1050.1 ( Figure 4D ) and NTD-203 directed infection-enhancing Ab, DH1052 (Figure 4E) 

DH1052 lacked neutralization of SARS-CoV-2 MA10 (Figure S4G-H) . DH1052 or a control influenza Ab CH65 227 was given 12 hours prior to SARS-CoV-2 MA10 infection ( Figure 5A) 

Cynomolgus macaques were infused with 10 mg of Ab per kg body weight and three days later challenged 237 intranasally and intratracheally with 10 5 PFU of SARS-CoV-2 ( Figure 5G) neutralizing Abs that also mediated in vitro infection-enhancement (Figures 6A-B) . Aged BALB/c mice were 262 injected intraperitoneally with 300 µg of Ab, and challenged with a SARS-CoV-2 mouse-adapted 2AA MA isolate (Figures 7H-K) , but protected only a subset of infused 288 monkeys. Two DH1046-infused monkeys had increased lung inflammation scores due to increased total areas of 289 inflammation compared to control Ab monkeys (Figures 7F and S5A ), but had no evidence of perivascular or 290 alveolar edema nor evidence of abnormal BAL cytokines (Table S5) . Thus, these two animals had more lung 291 involved with inflammatory macrophage infiltration but did not have pathological evidence of vascular leakage.

Comparing the DH1046 group to the control IgG group, viral nucleocapsid antigen in the lung was reduced 293 ( Figures 7G and S5A) . Thus, the weakly neutralizing Ab only partially limited virus replication and lung 294 inflammation.

In vitro infection enhancement by RBD Abs was dependent on Ab concentration, with lower levels of Ab

showing the highest magnitude of infection enhancement ( Figure 1G ). Therefore, we performed an additional 

UCSF Chimera--a visualization system for exploratory research and analysis

Cross-neutralization of SARS-CoV-2 by a human monoclonal 1100 SARS-CoV antibody

Safety and Efficacy of the BNT162b2 mRNA Covid-19

cryoSPARC: algorithms for rapid 1105 unsupervised cryo-EM structure determination

Convergent antibody responses to SARS-CoV-2 in 1108 convalescent individuals

COVID-19, MERS, and SARS in a nonhuman primate model

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from 1114 disease in a small animal model

Conceptual Approaches to Modulating Antibody Effector Functions and 1116 Circulation Half-Life

Antibody potency, effector function, and 1119 combinations in protection and therapy for SARS-CoV-2 infection in vivo

A Bayesian view on cryo-EM structure determination

Processing of Structurally Heterogeneous Cryo-EM Data in RELION

The PyMOL Molecular Graphics System

Pandemic 1125 Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19

Broad-spectrum antiviral GS-5734 inhibits both epidemic and 1128 zoonotic coronaviruses

A 1130 human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Automated molecular microscopy: the new Leginon system

Epitopes required for 1135 antibody-dependent enhancement of Ebola virus infection

How innate immune mechanisms contribute to antibody-enhanced 1137 viral infections

Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry

Enhancement of antibody functions through Fc multiplications

Epitopes in Humans Elicited both Enhancing and Neutralizing 1147 Effects on Infection in Non-human Primates

Antibody-dependent SARS coronavirus infection is mediated by antibodies 1150 against spike proteins

Broad neutralization of SARS-related viruses by human 1153 monoclonal antibodies

Broadly neutralizing human antibody that recognizes the 1156 receptor-binding pocket of influenza virus hemagglutinin

Virological assessment of hospitalized patients with COVID-1159 2019

Rapid cloning of high-affinity human monoclonal antibodies against 1162 influenza virus

Structural Basis for Potent Neutralization of 1165 Betacoronaviruses by Single-Domain Camelid Antibodies

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

A 1170 noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

SARS-coronavirus replication in human peripheral monocytes/macrophages

Antibody-dependent enhancement of SARS coronavirus infection and its role in 1177 the pathogenesis of SARS

Antibody-dependent infection of human macrophages by severe acute respiratory 1180 syndrome coronavirus

DNA vaccine protection against SARS-CoV-2 in rhesus 1183 macaques

Inborn errors of type I IFN immunity in patients with life-threatening

COVID-19

MotionCor2: 1188 anisotropic correction of beam-induced motion for improved cryo-electron microscopy

Structural basis for the neutralization of SARS-CoV-2 by an 1192 antibody from a convalescent patient

Active replication of Middle East respiratory syndrome coronavirus and aberrant 1195 induction of inflammatory cytokines and chemokines in human macrophages: implications for 1196 pathogenesis

Structure-Based Design with Tag-Based Purification and In-Process 1199

Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes

Potently neutralizing and protective human antibodies against 1203 SARS-CoV-2

Rapid isolation and profiling of a diverse panel of human 1206 monoclonal antibodies targeting the SARS-CoV-2 spike protein

CoV-2 (B) E gene sgRNA, (C) N gene sgRNA and (D) E gene total viral RNA

CoV-2 (E) E gene sgRNA, (F) N gene sgRNA and (G) E gene total viral RNA in nasal swab on Day 2 1322

Sections of the left caudal (Lc), right middle (Rm), and right caudal (Rc) lung were 1324 evaluated and scored for the presence of inflammation by hematoxylin and eosin (H&E) staining. (H) Summary of 1325 inflammation scores. Symbols indicate the sums of Lc, Rm, and Rc scores in each animal

IHC) staining for the presence of SARS-CoV-2 nucleocapsid in lungs. (J) Summary 1328 of IHC scores. Symbols indicate the sums of Lc, Rm, and Rc scores in each animal. (K) Representative images of 1329 lung IHC staining

Statistical significance in all the panels were determined using Wilcoxon rank sum exact 1331 test. Asterisks show the statistical significance between indicated group and CH65 control group: ns, not significant

Different doses of a cross-neutralizing Ab DH1047 treatments do not enhance SARS-CoV-2 1335 replication in vivo

Three days post-infusion, 10 5 PFU of SARS-CoV-2 challenge via intranasal and 1339 intratracheal routes. Viral load including viral RNA and subgenomic RNA (sgRNA) were measured at the 1340 indicated pre-challenge and post-challenge timepoints

B) Serum human IgG concentrations at Day 2

Day 2 serum neutralization titers shown as the reciprocal serum dilution that inhibits 50% (ID 50 ) of SARS

CoV-2 replication in Vero cells. 1345 (D-E) SARS-CoV-2 (D) E gene sgRNA and (E) N gene sgRNA in bronchoalveolar lavage (BAL) on Day 2 and

N gene sgRNA in nasal swab on Day 2 and Day 4 post challenge. 1348 (H-I) Lung inflammation. Sections of the left caudal (Lc), right middle (Rm), and right caudal (Rc) lung were 1349 evaluated and scored for the presence of inflammation by hematoxylin and eosin (H&E) staining. (H) Summary of 1350 inflammation scores. Symbols indicate the sums of Lc, Rm, and Rc scores in each animal

IHC) staining for the presence of SARS-CoV-2 nucleocapsid in lungs. (J) Summary 1353 of IHC scores. Symbols indicate the sums of Lc, Rm, and Rc scores in each animal. (K) Representative images of 1354 lung IHC staining

Statistical significance in all the panels were determined using Wilcoxon rank sum exact 1356 test. Asterisks show the statistical significance between indicated group and CH65 control group: ns, not significant

Supplementary Items (available online as excel sheet or PDF format) by Luminex assay. The animal (BB536A) in DH1052 group that exhibited substantially more severe 1377 disease and cytokine expression was marked in red

Supplementary Data 1. Cryo-EM information

NTD antibodies exhibited infection enhancement in vitro but not in vivo • Neutralizing or infection-enhancing NTD antibodies bound distinct epitopes • In vitro infection-enhancing antibodies protected from SARS-CoV-2 in vivo • Cross-reactive RBD neutralizing antibodies were protective--most potent

Convalescent human-derived SARS-CoV-2 RBD and NTD antibodies mediated neutralization as well as infection-enhancement in vitro, yet infusion of these antibodies in mice or cynomolgus macaques resulted in protection from viral replication

Representative micrograph, (middle) CTF fit and (right) Representative 2D class averages for (A) DH1041-Spike-2P (S2P) complex, (B) DH1043-S2P complex

Global and Local map resolutions for DH1041/S-2P complex. (A) Cryo-EM reconstruction of

Top two rows show refined maps, bottom row shows the FSC curve for each corresponding map. (B) Left. Refined cryo-EM map that was used for model building colored by local resolution. Right. Zoomed-in view of the S2 region with cryo-EM map shown as blue mesh and underlying fitted model as sticks and colored by element. (C) Zoomed-in view of the DH1047 interface with RBD. The cryo-EM map is shown as a blue mesh with underlying fitted model shown in cartoon representation

A) Cryo-EM reconstruction of DH1050.1 bound to 3-RBD-down 2P spike. (B) Fourier shell correlation curves. (C) Left. Refined cryo-EM map colored by local resolution for the DH1050.1 bound to 3-RBD-down 2P spike. Right. Zoomed-in view of the S2 region with cryo-EM map shown as blue mesh and underlying fitted model as sticks and colored by element

Global and Local map resolutions for DH1052/S-2P complex. (A) Cryo-EM reconstruction of DH1052 bound to 3-RBD-down stabilized Spike "2P" (S-2P). (B) Fourier shell correlation curves. (C) Left. Refined cryo-EM map colored by local resolution for the DH1052

Zoomed-in view of the S2 region with cryo-EM map shown as blue mesh and underlying fitted model as sticks and colored by element. (D) Cryo-EM reconstruction of DH1052

For cytokine profiling, 7-fold concentrated cynomolgus macaques BAL samples were measured using a 25-841 analyte multiplex bead array (Millipore, catalog # PRCYT2MAG40K) including sCD137, Eotaxin, sFasL, FGF-2, 842 Fractalkine, Granzyme A, Granzyme B, IL-1α, IL-2, IL-4, IL-6, IL-16, IL-17A, IL-17E/IL-25, IL-21, IL-22, IL- then 50 µL of diluted sera or monoclonal Ab 3-fold serially diluted in assay buffer (1000-0.45ng/mL) was added to 855 a 96-well plate and mixed with 50 µL assay buffer containing 2500 BSA-conjugated beads (negative control) plus 856 2500 HA or Spike-conjugated beads. The plate was shaken at 800RPM for 60 minutes at room temperature, 857 washed twice in assay buffer and then 100 µL 4 µg/mL biotin-conjugated mouse anti-human IgG Fc clone H2 858 (Southern Biotech) in assay buffer was added to every well. The plate was shaken at 800 RPM for 30 minutes at 859 room temperature, washed two times in assay buffer and then 50 µL 4 µg/mL streptavidin-r-phycoerythrin 860 (Invitrogen) in assay buffer was added to every well. The plate was shaken at 800 RPM for 30 minutes at room 861 temperature and washed twice in assay buffer. Beads were resuspended in 150 µL/well assay buffer, shaken at 800 862 RPM for 15 minutes at room temperature and then analyzed on a BioPlex 200 bead reader (Bio-Rad). Sera antigen-863 specific Ab concentrations were calculated using Bio-Plex Manager software (Bio-Rad) by extrapolating from the 864 results of the serially-diluted monoclonal Ab. Sera with Abs above the upper limit of quantitation were re-assayed 865 at 1:1000 or 1:5000. The limit of detection (LOD) for this assay is 0.278 µg/mL. Table S1 and S2 that have pseudovirus neutralization data (n=59) or SARS-CoV-2 micro-1234 neutralization assay data (n=80) were used in this analysis. P-value and r were indicated for each figures.